Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post-marketing surveillance study.
apremilast
plaque psoriasis
post‐marketing surveillance
psoriatic arthritis
safety
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
22 May 2024
22 May 2024
Historique:
revised:
04
04
2024
received:
11
01
2024
accepted:
29
04
2024
medline:
22
5
2024
pubmed:
22
5
2024
entrez:
22
5
2024
Statut:
aheadofprint
Résumé
The safety and efficacy of apremilast in psoriatic disease has been demonstrated in clinical trials, including in Japanese patients. This post-marketing surveillance study was conducted after approval of apremalast in Japan in 2016 to evaluate the safety and effectiveness of the drug in Japanese patients with plaque psoriasis (PsO) and psoriatic arthritis (PsA) in routine clinical practice. Patients (enrolled between September 1, 2017, and August 31, 2019), were observed for 12 months after apremilast treatment initiation or until discontinuation or withdrawal. Safety was assessed by evaluating adverse reactions (ARs) and serious ARs. Effectiveness measures in PsO included the proportion of patients who achieved global improvement and Physician's Global Assessment (PGA) scores of 0/1 and the change from baseline in the Dermatology Life Quality Index (DLQI) after 6 and 12 months treatment. The safety analysis set included 1063 patients (PsO, n = 992; PsA, n = 127). ARs and serious ARs were reported in 29.4% and 0.7% of patients, respectively; most occurred <1 month after apremilast initiation. There were no reports of fatal ARs, serious infections, hypersensitivity, or vasculitis. No new safety signals were identified. Among the key survey items, gastrointestinal disorders were the most common ARs (21.3%). In patients with PsO, after 6 and 12 months of treatment, effectiveness rates of achieving highly effective or effective global improvement of were 90.9% and 93.8%; PGA 0/1 was achieved by 42.7% and 58.1% of patients; mean decrease from baseline in total DLQI score was 4.2 (p < 0.0001) and 5.7 (p < 0.0001), respectively. Effectiveness was evaluated in a small number of patients with PsA for some measures; after 6 and 12 months of treatment, improvements were observed in global improvement effectiveness rates, Disease Activity Score in 28 Joints score, Visual Analog Scale score, and DLQI score. We conclude that orally administered apremilast was well tolerated and effective in Japanese patients with PsO and/or PsA enrolled in this post-marketing surveillance study.
Identifiants
pubmed: 38775204
doi: 10.1111/1346-8138.17270
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Amgen K.K.
Informations de copyright
© 2024 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
Références
Keating GM. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2017;77:459–472.
Torres T, Puig L. Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2018;19(1s):23–32.
Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26:2016–2029.
Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380:738–746.
Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RGB, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of Apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37–49.
Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387–1399.
Cutolo M, Myerson GE, Fleischmann RM, Lioté F, Díaz‐González F, van den Bosch F, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43:1724–1734.
Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75:1065–1073.
Kavanaugh A, Mease PJ, Gomez‐Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo‐controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020–1026.
Wells AF, Edwards CJ, Kivitz AJ, Bird P, Nguyen D, Paris M, et al. Apremilast monotherapy in DMARD‐naive psoriatic arthritis patients: results of the randomized, placebo‐controlled PALACE 4 trial. Rheumatology (Oxford). 2018;57:1253–1263.
Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: efficacy, safety and tolerability results from a phase 2b randomized controlled trial. J Dermatol. 2017;44:873–884.
Amgen. Japanese prescribing information for apremilast (in Japanese). Available from: https://wwwamgencojp/‐/media/Themes/CorporateAffairs/amgen‐co‐jp/amgen‐co‐jp/pdf/3,‐d‐,0/3,‐d‐,3/Otezla/package_insertpdf
New Drugs Approved in FY 2016. 2016. Available from: https://www.pmda.go.jp/files/000232770.pdf
Pascoe VL, Enamandram M, Corey KC, Cheng CE, Javorsky EJ, Sung SM, et al. Using the physician global assessment in a clinical setting to measure and track patient outcomes. JAMA Dermatol. 2015;151:375–381.
Finlay AY, Khan GK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–216.
Salaffi F, Ciapetti A, Carotti M, Gasparini S, Gutierrez M. Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. Biomed Res Int. 2014;2014:528105.
Okubo Y, Takahashi H, Hino R, Endo K, Kikuchi S, Ozeki Y, et al. Efficacy and safety of apremilast in the treatment of patients with mild‐to‐moderate psoriasis in Japan: results from PROMINENT, a phase 3b, open‐label, single‐arm study. Dermatol Ther. 2022;12:1469–1480.
Kishimoto M, Komine M, Hioki T, Kamiya K, Sugai J, Ohtsuki M. Real‐world use of apremilast for patients with psoriasis in Japan. J Dermatol. 2018;45:1345–1348.
Kishimoto M, Komine M, Kamiya K, Sugai J, Ohtsuki M. Drug survival of apremilast in a real‐world setting. J Dermatol. 2019;46:615–617.
Kishimoto M, Komine M, Kamiya K, Sugai J, Kuwahara A, Ohtsuki M. Four‐year drug survival of apremilast in patients with psoriasis. J Dermatol. 2023;50:960–963.
Saruwatari H. Real‐world experiences of apremilast in clinics for Japanese patients with psoriasis. J Dermatol. 2019;46:1166–1169.
Ohata C, Ohyama B, Kuwahara F, Katayama E, Nakama T. Real‐world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis. J Dermatolog Treat. 2019;30:383–386.
Mease PJ, Hatemi G, Paris M, Cheng S, Maes P, Zhang W, et al. Apremilast long‐term safety up to 5 years from 15 pooled randomized, placebo‐controlled studies of psoriasis, psoriatic arthritis, and Behçet's syndrome. Am J Clin Dermatol. 2023;24:809–820.
Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S, et al. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). J Dermatol. 2023;50:e41–e68.
Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S, et al. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis. J Dermatol. 2023;50:e138–e150.
Amgen. Interview form for Apremilast (in Japanese). Available from: https://wwwamgencojp/−/media/Themes/CorporateAffairs/amgen‐co‐jp/amgen‐co‐jp/pdf/3,‐d‐,0/3,‐d‐,3/Otezla/interviewformpdf
Branisteanu DE, Nicolescu AC, Branisteanu DC, Branisteanu C, Dragoi A, Bogdanici C, et al. Cardiovascular comorbidities in psoriasis (review). Exp Ther Med. 2022;23:152.
Larsen MH, Hagen KB, Krogstad AL, Wahl AK. Shared decision making in psoriasis: a systematic review of quantitative and qualitative studies. Am J Clin Dermatol. 2019;20:13–29.
Takano‐Kawasaki S, Sato E, Yamaguchi K, Imafuku S. Trends in prescriptions of oral medications for psoriasis: a single‐center retrospective study. J Dermatol. 2023;50:82–88.
Kamiya K, Oiso N, Kawada A, Ohtsuki M. Epidemiological survey of the psoriasis patients in the Japanese Society for Psoriasis Research from 2013 to 2018. J Dermatol. 2021;48:864–875.